X
Wedesday, May 21, 2025
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

Content Team by Content Team
27th April 2023
in Drug Development, News
Tumors Can Get Destroyed By Bacteria-Aid To Immune System

R21/Matrix-M happens to have a saponin-based adjuvant, Matrix-M, which goes on to enhance the immune response, thereby making it more viable and also durable.

It is well to be noted that the adjuvant stimulates the entry of the antigen-presenting cells within the injection site and also goes on to elevate the antigen presentations within the local lymph nodes. Apparently, this technology has been used pretty accurately in the COVID-19 vaccine developed by Novavax.

In case of phase II trials, malaria vaccine showed high levels of efficacy and safety in children who went on to receive a booster dose a year after a primary three-dosage course.

Significantly, the booster dose of R21/Matrix-M continued to be in sync with the WHO’s Malaria Vaccine Technology Roadmap objective of a vaccination that possesses a minimum 75% rate of efficacy.

The 2021 result from the Phase IIb trial followed it, which reported that R21/Matrix-M showed a high level of efficacy of almost 77%. According to the current data, the ongoing Phase III trial, which went on to enrol 4800 kids, showed high efficacy levels as well as a reassuring safety profile. More inferences from the R21/Matrix-M vaccine trials are anticipated to come later in 2023.

The R21/Matrix-M malaria vaccine, which was developed by the University of Oxford, has been given the go-ahead to be used in Ghana in the middle of April and is also authorised to be used in Nigeria on April 17.

The malaria vaccine approval in Ghana was the first in the world. It was granted full national licensure by the Ghanian Food and Drugs Authority and was authorised to be used for children between 5 months and 36 months. Apparently, this age group happens to be at the highest risk of malarial deaths.

As per Adrian Hill, the chief investigator of the R21/Matrix-M programme as well as the director of Oxford University’s Jenner Institute at the Nuffield Department of Medicine, this feat marks the end of 30 years of Oxford’s malaria vaccine analysis. He added that Ghana’s regulatory approval happens to be a vital step in helping to reduce the more than half a million deaths that occur every year.

As per Professor Hill, the collaboration with the vaccine’s manufacturer held the key to accomplished and large-scale manufacturing as well as rapid development. According to the manufacturer, they have the capacity to manufacture more than 200 million doses.

Previous Post

United Cargo - after Opticooler RAP, now also Opticooler RKN certified

Next Post

Neurodevelopmental Issue Leads To Testicular Cancer Risk

Related Posts

Articles

Continuous Manufacturing is Improving Biopharma Production

17th March 2025
Articles

AI in Drug Commercialization Market to Grow CAGR 24% by 2032

17th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Insights

Advancing Asia-Pacific Healthcare & Biopharma Innovation

7th March 2025
Insights

Generative AI in Pharma: Opportunities & Challenges

7th March 2025
Drug Development

Global Biopharma Market to Hit $566B by 2032

7th March 2025
Next Post
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

Neurodevelopmental Issue Leads To Testicular Cancer Risk

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications